Core Insights - Firefly Neuroscience, Inc. is leveraging its FDA-cleared BNA™ platform to provide objective measures of drug efficacy and cognitive change, positioning itself as a leader in neuropharmacology and psychiatry [1][6] Study Summaries Study 1: Advancing Neuropharmacology with Novartis' MIJ821 - The first study focuses on MIJ821 (onfasprodil) and demonstrates the use of EEG in assessing its antidepressant effects, highlighting the drug's safety, pharmacokinetics, and pharmacodynamics [2][4] - Key findings indicate dose-dependent EEG changes, validating EEG as a pharmacokinetic-pharmacodynamic tool, and suggesting clinical potential for EEG-driven biomarker development [8] Study 2: Objective Cognitive Assessments in Major Depressive Disorder (MDD) Treatment - The second study evaluates an EEG-based tool for assessing cognitive changes in MDD patients treated with vortioxetine, showcasing the application of EEG in monitoring treatment efficacy [4][9] - Findings reveal that baseline brain activation latencies in MDD patients normalized post-treatment, indicating improved cognitive functioning [9] Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, with its BNA™ technology revolutionizing diagnostic and treatment monitoring methods [7][11] - The company has developed its BNA™ technology using AI and machine learning on a comprehensive database of over 17,000 patients, enhancing diagnostic accuracy and treatment evaluation [11]
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care